Efficacy of Ocrevus in Reducing Disease Activity
Ocrevus (ocrelizumab) has been shown to be effective in reducing disease activity in patients with multiple sclerosis (MS). [1] It was approved by the FDA in 2017 for the treatment of people with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Reduction in Disability Progression
Studies have demonstrated that Ocrevus can reduce disability progression and slow disease activity in patients with MS. The phase III trials, OCREVUS-303 and OCREVUS-305, showed that patients treated with Ocrevus had a 47% reduction in the risk of 12-week confirmed disability progression compared to Avonex (interferon beta-1a) and Rebif (interferon beta-1a). [1]
Relapse Rate Reduction
Ocrevus has also been shown to reduce the relapse rate in patients with RMS. In the OCREVUS-303 trial, patients treated with Ocrevus had a 47% reduction in annualized relapse rate (ARR) compared to Avonex and Rebif. [1]
Effectiveness in PPMS
In the OCREVUS-305 trial, Ocrevus was shown to reduce disability progression in patients with PPMS compared to placebo. Patients treated with Ocrevus had a 25% reduction in the risk of 12-week confirmed disability progression compared to placebo. [1]
Adverse Effects
While Ocrevus has been shown to be effective in reducing disease activity in patients with MS, it is not without potential adverse effects. Common side effects include infusion reactions, upper respiratory tract infections, and herpes infections. [1]
Patent Expiration
The patent for Ocrevus is set to expire in 2031, which may lead to the availability of biosimilars and generic alternatives. [2]
Regulatory Status
Ocrevus has been approved by regulatory agencies worldwide, including the FDA, EMA, and TGA, for the treatment of RMS and PPMS. [1]
Clinical Data
The clinical data for Ocrevus has been published in various peer-reviewed journals, including the New England Journal of Medicine and the Lancet Neurology. [1]
Sources:
[1] https://www.drugpatentwatch.com/drug/ocrevus
[2] https://www.drugpatentwatch.com/patent/US10281358B2
Note: This article contains affiliate links to DrugPatentWatch.com.